Announcements Trials
Browse Landscape

Phase

Phase 2 48Phase 1/2 22Phase 1 16Phase 3 4Phase EARLY_PHASE1 2Phase 4 2

Status

Unknown 1Terminated 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 6OTHER 4NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 4

Interventions

Cisplatin 294Radiotherapy 230Fluorouracil 201Cyclophosphamide 191Capecitabine 183Docetaxel 167Gemcitabine 165Oxaliplatin 162Carboplatin 161Paclitaxel 152Leucovorin 122Drug Therapy 119Dexamethasone 119Doxorubicin 112Etoposide 99Bevacizumab 91Cytarabine 87Vincristine 83Irinotecan 81Rituximab 77Epirubicin 71Prednisone 65Radiosurgery 63Methotrexate 62Surgical Procedures, Operative 61Radiation 60Radiotherapy, Intensity-Modulated 57Neoadjuvant Therapy 53Lenalidomide 52Letrozole 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × OTHER × ixazomib × Clear all
NCT05675319 2026-01-05

AlloRelapseMM

Universitätsklinikum Hamburg-Eppendorf

Phase 3 Terminated
28 enrolled
Plasma cell

Multiple Myeloma

NCT03720041 2021-06-15

FiTNEss

University of Leeds

Phase 3 Unknown
740 enrolled
Plasma cell

Multiple Myeloma

NCT03562169 2018-06-19

The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)

University of Leeds

Phase 3 Recruiting
406 enrolled
Plasma cell

Multiple Myeloma

NCT02406144 2017-11-30

Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma

PETHEMA Foundation

Phase 3 Completed
316 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡